Alkem Laboratories declared its Unaudited Financial Results for the quarter and nine months ended December 31, 2025. The Board approved the financial results and declared an Interim Dividend of ₹43/- per equity share (2150% on face value of ₹2/-) for FY2025-2026. The record date for this dividend payment is set for February 20, 2026, with payment commencing on March 6, 2026.
Board Meeting Outcome and Financial Results
The Board of Directors of Alkem Laboratories met on February 13, 2026, to review and approve the Unaudited Financial Results for both standalone and consolidated operations for the quarter and nine months ending December 31, 2025. The Board meeting commenced at 11:00 a.m. and concluded at 01:45 p.m.
Interim Dividend Declaration
A significant resolution passed was the declaration of an Interim Dividend of ₹43/- (Rupees forty-three only) per equity share for the financial year 2025-2026, based on a face value of ₹2/- per share. This corresponds to a 2150% dividend rate. The required record date for determining eligible shareholders is set for Friday, February 20, 2026. The dividend payment will commence on or from March 6, 2026.
Consolidated Financial Highlights (Q3 FY2026 vs. Previous Year)
The consolidated financial statement reveals key performance metrics:
- Total Income (Q3 FY2026): ₹38,799.2 million, compared to ₹34,672.7 million in Q3 FY2025.
- Profit Before Tax (Q3 FY2026): ₹7,812.0 million, up from ₹7,310.7 million in Q3 FY2025.
- Profit Attributable to Owners of the Company (Q3 FY2026): ₹6,360.2 million, against ₹6,258.2 million in Q3 FY2025.
- Earnings Per Share (Basic, Q3 FY2026): ₹53.19, compared to ₹52.34 in Q3 FY2025.
Key Notes on Financial Reporting
Several exceptional items influenced the results:
- An exceptional item of (₹527.9 million) was classified for the quarter and nine months, primarily related to the incremental impact analysis following the notification of four Labour Codes effective November 21, 2025.
- The consolidated results included the share of loss from an associate amounting to ₹5.0 million for the quarter.
- The company continues to operate in one reportable segment: “Pharmaceuticals”, thus no separate segment disclosures were required.
Standalone Financial Highlights (Q3 FY2026 vs. Previous Year)
Focusing on the standalone entity’s continuing operations:
- Total Income (Q3 FY2026): ₹26,228.0 million, an increase from ₹24,560.1 million in Q3 FY2025.
- Profit Before Tax from Continuing Operations (Q3 FY2026): ₹7,061.5 million, up from ₹7,384.0 million in Q3 FY2024 (Note: The Q3 FY2025 figure was ₹8,007.1 million before exceptional items).
- The standalone results were impacted by Exceptional Items of (₹381.7 million) in the quarter.
The standalone results also incorporated the impact of the transfer of the Generic Business Undertaking to Alkem Wellness Limited, which occurred on October 1, 2025, necessitating restatement of prior periods as discontinued operations.
Source: BSE
